Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology

15-03-2024 | Hypothyroidism | REVIEW ARTICLE

Association between thyroid disorders and extra-thyroidal cancers, a review

Authors: Xin Jia, Jingru Li, Zongliang Jiang

Published in: Clinical and Translational Oncology

Login to get access

Abstract

Thyroid hormone has been shown to have both tumor-promoting and tumor-suppressing actions, which has led to significant debate over its involvement in the development of cancer. Proliferation, apoptosis, invasiveness, and angiogenesis are all aspects of cancer that are affected by the thyroid hormones T3 and T4, according to research conducted in animal models and in vitro experiments. The effects of thyroid hormones on cancer cells are mediated by many non-genomic mechanisms, one of which involves the activation of the plasma membrane receptor integrin αvβ3. Typically, abnormal amounts of thyroid hormones are linked to a higher occurrence of cancer. Both benign and malignant thyroid disorders were found to be associated with an increased risk of extra-thyroidal malignancies, specifically colon, breast, prostate, melanoma, and lung cancers. The purpose of this review was to shed light on this link to define which types of cancer are sensitive to thyroid hormones and, as a result, are anticipated to respond favorably to treatment of the thyroid hormone axis.
Literature
1.
Christensen DH, Veres K, Ording AG, Jørgensen JOL, Cannegieter SC, Thomsen RW, et al. Risk of cancer in patients with thyroid disease and venous thromboembolism. Clin Epidemiol. 2018;10:907–15.PubMedPubMedCentralCrossRef
2.
Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K. Cancer risk in patients hospitalised for graves’ disease: a population-based cohort study in Sweden. Br J Cancer. 2010;102(9):1397–9.PubMedPubMedCentralCrossRef
3.
Gao T-H, Liao W, Lin L-T, Zhu Z-P, Lu M-G, Fu C-M, et al. Curcumae rhizoma and its major constituents against hepatobiliary disease: pharmacotherapeutic properties and potential clinical applications. Phytomedicine. 2022;102: 154090.PubMedCrossRef
4.
Dou M, Zhu K, Fan Z, Zhang Y, Chen X, Zhou X, et al. Reproductive hormones and their receptors may affect lung cancer. Cell Physiol Biochem. 2017;44(4):1425–34.PubMedCrossRef
5.
Kuklinski LF, Zens MS, Perry AE, Gossai A, Nelson HH, Karagas MR. Sex hormones and the risk of keratinocyte cancers among women in the United States: a population-based case–control study. Int J Cancer. 2016;139(2):300–9.PubMedPubMedCentralCrossRef
6.
Boursi B, Haynes K, Yang YX. Thyroid dysfunction thyroid hormone replacement and colorectal cancer risk. J Natl Cancer Instit. 2015;107(6):djv084.CrossRef
7.
de la Cruz-Merino L, Grande-Pulido E, Albero-Tamarit A, Albero-Tamarit A. Cancer and immune response: old and new evidence for future challenges. Oncologist. 2008;13(12):1246–54.PubMedCrossRef
8.
Salehi S, Mahmoudinezhad Dezfouli SM, Azadeh H, Khosravi S. Immune dysregulation and pathogenic pathways mediated by common infections in rheumatoid arthritis. Folia Microbiol. 2023;68(1):11.
9.
Dezfouli SMM, Salehi S, Khosravi S. Pathogenic and therapeutic roles of cytokines in Kawasaki diseases. Clin Chim Acta. 2022;532:21–8.CrossRef
10.
Fiore E, Giustarini E, Mammoli C, Fragomeni F, Campani D, Muller I, et al. Favorable predictive value of thyroid autoimmunity in high aggressive breast cancer. J Endocrinol Invest. 2007;30:734–8.PubMedCrossRef
11.
Medghalchi A, Akbari M, Alizadeh Y, Moghadam RS. The epidemiological characteristics of patients with thyroid eye disease in a referral center in northern Iran. J Curr Ophthal. 2018;30(4):353–8.CrossRef
12.
Lun Y, Wu X, Xia Q, Han Y, Zhang X, Liu Z, et al. Hashimoto’s thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol-Head Neck Sur. 2013;148(3):396–402.CrossRef
13.
14.
Boi F, Minerba L, Lai M, Marziani B, Figus B, Spanu F, et al. Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules. J Endocrinol Invest. 2013;36:313–20.PubMed
15.
Kunjumohamed FP, Al-Busaidi NB, Al-Musalhi HN, Al-Shereiqi SZ, Al-Salmi IS. The prevalence of thyroid cancer in patients with hyperthyroidism. Saudi Med J. 2015;36(7):874.PubMedPubMedCentralCrossRef
16.
Liu Y, Zhang Y, Tan Z, Wang J, Hu Y, Sun J, et al. Lysyl oxidase promotes anaplastic thyroid carcinoma cell proliferation and metastasis mediated via BMP1. Gland Surg. 2022;11(1):245.PubMedPubMedCentralCrossRef
17.
Ghaffari HR, Kamari Z, Ranaei V, Pilevar Z, Akbari M, Moridi M, et al. The concentration of potentially hazardous elements (PHEs) in drinking water and non-carcinogenic risk assessment: a case study in Bandar Abbas, Iran. Environ Res. 2021;201:111567.PubMedCrossRef
18.
Ortega-Olvera C, Ulloa-Aguirre A, Ángeles-Llerenas A, Mainero-Ratchelous FE, González-Acevedo CE, Hernández-Blanco ML, et al. Thyroid hormones and breast cancer association according to menopausal status and body mass index. Breast Cancer Res. 2018;20(1):94.PubMedPubMedCentralCrossRef
19.
Teumer A, Chaker L, Groeneweg S, Li Y, Di Munno C, Barbieri C, et al. Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation. Nat Commun. 2018;9(1):4455.ADSPubMedPubMedCentralCrossRef
20.
Davies T. The thyrotropin receptors spread themselves around. J Clin Endocrinol Metab. 1994;79(5):1232–3.PubMed
21.
Chen YK, Lin CL, Chang YJ, Cheng FTF, Peng CL, Sung FC. Cancer risk in patients with Graves’ disease: a nationwide cohort study. Thyroid. 2013;23(7):879–84.PubMedPubMedCentralCrossRef
22.
Gharehbeglou M, Arjmand G, Haeri MR, Khazeni M. Nonselective mevalonate kinase inhibitor as a novel class of antibacterial agents. Cholesterol. 2015;2015:147601.PubMedPubMedCentralCrossRef
23.
24.
Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nat Rev Endocrinol. 2016;12(2):111–21.PubMedCrossRef
25.
Freindorf M, Furlani TR, Kong J, Cody V, Davis FB. Combined QM/MM study of thyroid and steroid hormone analogue interactions with αvβ3 integrin. J Biomed Biotechnol. 2012;2012:959057.PubMedPubMedCentralCrossRef
26.
Lin HY, Sun GL, Tang HY, Lin C, Luidens MK, Mousa SA. L-Thyroxine vs. 3, 5, 3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol-Cell Physiol. 2009;296(5):980–91.CrossRef
27.
28.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.PubMedPubMedCentralCrossRef
29.
Paschke R. Molecular pathogenesis of nodular goiter. Langenbeck’s Arch Surg. 2011;396:1127–36.CrossRef
30.
31.
Sorrenti S, Dolcetti V, Fresilli D, DelGaudioPacini GP, Huang P, et al. The role of CEUS in the evaluation of thyroid cancer: from diagnosis to local staging. J Clin Med. 2021;10(19):4559.PubMedPubMedCentralCrossRef
32.
33.
Wang Y, Liyanarachchi S, Miller KE, Nieminen TT, Comiskey DF Jr, Li W, et al. Identification of rare variants predisposing to thyroid cancer. Thyroid. 2019;29(7):946–55.PubMedPubMedCentralCrossRef
34.
Yang SP, Ngeow J. Familial non-medullary thyroid cancer: unraveling the genetic maze. Endocr Relat Cancer. 2016;23(12):R577–95.CrossRef
35.
Nikiforov YE, Biddinger PW, Thompson LD. Diagnostic pathology and molecular genetics of the thyroid: a comprehensive guide for practicing thyroid pathology. Philadelphia, PA: Lippincott Williams and Wilkins; 2012.
36.
Cui B, Wu Z, Yu B, Li Y, Liu H. The diagnostic value of BRAF V600E gene detection combined with DNA ploidy analysis in thyroid cancer. Discov Med. 2023;35(179):1064–70.PubMedCrossRef
37.
Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–90.PubMedCentralCrossRef
38.
39.
Hall LC, Salazar EP, Kane SR, Liu N. Effects of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol. 2008;109(1–2):57–66.PubMedCrossRef
40.
Tashireva L, Grigoryeva E, Alifanov V, Iamshchikov P, Zavyalova M, Perelmuter V. Spatial heterogeneity of integrins and their ligands in primary breast tumors. Discov Med. 2023;35(178):910–20.PubMedCrossRef
41.
Tosovic A, Bondeson A-G, Bondeson L, Ericsson U-B, Malm J, Manjer J. Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women. Breast Cancer Res. 2010;12:1–12.CrossRef
42.
43.
Ye X-X, Ren Z-Y, Vafaei S, Zhang J-M, Song Y, Wang Y-X, et al. Effectiveness of Baduanjin exercise on quality of life and psychological health in postoperative patients with breast cancer: a systematic review and meta-analysis. Integr Cancer Ther. 2022;21:15347354221104092.PubMedPubMedCentralCrossRef
44.
Søgaard M, Farkas DK, Ehrenstein V, Jørgensen JOL, Dekkers OM, Sørensen HT. Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study. Eur J Endocrinol. 2016;174(4):409–14.PubMedCrossRef
45.
Ortega-Olvera C, Ulloa-Aguirre A, Ángeles-Llerenas A, Mainero-Ratchelous FE, González-Acevedo CE, Hernández-Blanco ML. Thyroid hormones and breast cancer association according to menopausal status and body mass index. Breast Cancer Res. 2018;20:1–14.CrossRef
46.
Huang J, Jin L, Ji G, Xing L, Xu C, Xiong X, et al. Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine. BMC Cancer. 2013;13:1–12.ADSCrossRef
47.
Villa NM, Li N, Yeh MW, Hurvitz SA, Dawson NA, Leung AM. Serum thyrotropin concentrations are not predictive of aggressive breast cancer biology in euthyroid individuals. Endocr Pract. 2015;21(9):1040–5.PubMedPubMedCentralCrossRef
48.
Brandt J, Borgquist S, Almgren P, Försti A, Huss L, Melander O, et al. Thyroid-associated genetic polymorphisms in relation to breast cancer risk in the Malmö diet and cancer study. Int J Cancer. 2018;142(7):1309–21.PubMedCrossRef
49.
Anil C, Guney T, Gursoy A. The prevalence of benign breast diseases in patients with nodular goiter and Hashimoto’s thyroiditis. J Endocrinol Invest. 2015;38:971–5.PubMedCrossRef
50.
Giustarini E, Pinchera A, Fierabracci P, Roncella M, Fustaino L, Mammoli C, et al. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol. 2006;154(5):645–9.PubMedCrossRef
51.
52.
L’Heureux A, Wieland D, Weng C, Chen Y, Lin C, Lin T, et al. Association between thyroid disorders and colorectal cancer risk in adult patients in Taiwan. JAMA Netw Open. 2019;2(5):e193755.PubMedPubMedCentralCrossRef
53.
Rennert G, Rennert HS, Pinchev M, Gruber SB. A case–control study of levothyroxine and the risk of colorectal cancer. J Natl Cancer Inst. 2010;102(8):568–72.PubMedPubMedCentralCrossRef
54.
Goldman MB, Monson RR, Maloof F. Cancer mortality in women with thyroid disease. Can Res. 1990;50(8):2283–9.
55.
Andersen SL, Olsen J, Wu CS, Laurberg P. Smoking reduces the risk of hypothyroidism and increases the risk of hyperthyroidism: evidence from 450 842 mothers giving birth in Denmark. Clin Endocrinol. 2014;80(2):307–14.CrossRef
56.
57.
VanCutsemSagaert EX, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–64.CrossRef
58.
Razmi M, Ghods R, Vafaei S, Sahlolbei M, Saeednejad Zanjani L, Madjd Z. Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis. Cancer Cell Int. 2021;21:1–20.CrossRef
59.
Kirkegård J, Farkas DK, Jørgensen JOL, Cronin-Fenton D. Hyper- and hypothyroidism and gastrointestinal cancer risk: a Danish nationwide cohort study. Endocr Connect. 2018;7(11):1129–35.PubMedPubMedCentralCrossRef
60.
Reddy A, Dash C, Leerapun A, Mettler TA, Stadheim LM, Lazaridis KN, et al. Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin Gastroenterol Hepatol. 2007;5(1):118–23.PubMedCrossRef
61.
Wen L, Cheng F, Zhou Y, Yin C. MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2. Saudi J Gastroenterol. 2015;21(5):313.PubMedPubMedCentralCrossRef
62.
Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, et al. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology. 2009;49(5):1563–70.PubMedCrossRef
63.
Frau C, Loi R, Petrelli A, Perra A, Menegon S, Kowalik MA, et al. Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats. Hepatology. 2015;61(1):249–59.PubMedCrossRef
64.
65.
He B, Sun H, Bao M, Li H, He J, Tian G, et al. A cross-cohort computational framework to trace tumor tissue-of-origin based on RNA sequencing. Sci Rep. 2023;13(1):15356.ADSPubMedPubMedCentralCrossRef
66.
67.
Cui Y, Wang X, Lin F, Li W, Zhao Y, Zhu F, et al. MiR-29a-3p improves acute lung injury by reducing alveolar epithelial cell PANoptosis. Aging Dis. 2022;13(3):899.PubMedPubMedCentralCrossRef
68.
Mohamed FEZA, Abdelaziz AO, Kasem AH, Ellethy T, Gayyed MF. Thyroid hormone receptor α1 acts as a new squamous cell lung cancer diagnostic marker and poor prognosis predictor. Sci Rep. 2021;11(1):7944.ADSPubMedPubMedCentralCrossRef
69.
70.
Latteyer S, Christoph S, Theurer S, Hönes GS, Schmid KW, Führer D, et al. Thyroxine promotes lung cancer growth in an orthotopic mouse model. Endocr Relat Cancer. 2019;26(6):565–74.PubMedCrossRef
71.
72.
Liu W, Zhi F-H, Zheng S-Y, Yang H-S, Geng X-J, Luo H-H, et al. Hypothyroidism reduces the risk of lung cancer through oxidative stress response and the PI3K/Akt signaling pathway: An RNA-seq and Mendelian randomization study. Heliyon. 2023;9(12):e22661.PubMedPubMedCentralCrossRef
73.
Ellerhorst J, Cooksley C, Grimm E. Autoimmunity and hypothyroidism in patients with uveal melanoma. Melanoma Res. 2001;11(6):633–7.PubMedCrossRef
74.
75.
Oakley GM, Curtin K, Layfield L, Jarboe E, Buchmann LO, Hunt JP. Increased melanoma risk in individuals with papillary thyroid carcinoma. JAMA Otolaryngol Head Neck Surg. 2014;140(5):423–7.PubMedCrossRef
76.
Tavares C, Melo M, Cameselle-Teijeiro JM, Soares P, Sobrinho-Simoes M. Endocrine tumours: genetic predictors of thyroid cancer outcome. Eur J Endocrinol. 2016;174(4):R117–26.PubMedCrossRef
77.
Cicenas J, Tamosaitis L, Kvederaviciute K, Tarvydas R, Staniute G, Kalyan K, et al. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Med Oncol. 2017;34:1–11.CrossRef
78.
Potrony M, Puig-Butille J, Ribera-Sola M, Iyer V, Robles-Espinoza C, Aguilera P, et al. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families. Br J Dermatol. 2019;181(1):105–13.PubMedPubMedCentralCrossRef
79.
Wong K, Robles-Espinoza CD, Rodriguez D, Rudat SS, Puig S, Potrony M. Association of germline missense variant with familial melanoma. JAMA Dermatol. 2019;155(5):604–9.PubMedCrossRef
80.
Srivastava A, Miao B, Skopelitou D, Kumar V, Kumar A, Paramasivam N, et al. A germline mutation in the POT1 gene is a candidate for familial non-medullary thyroid cancer. Cancers. 2020;12(6):1441.PubMedPubMedCentralCrossRef
81.
Chan YX, Knuiman MW, Divitini ML, Brown SJ, Walsh J, Yeap BB. Lower TSH and higher free thyroxine predict incidence of prostate but not breast, colorectal or lung cancer. Eur J Endocrinol. 2017;177(4):297–308.PubMedCrossRef
82.
83.
84.
Aranda A, Martínez-Iglesias O, Ruiz-Llorente L, García-Carpizo V, Zambrano A. Thyroid receptor: roles in cancer. Trends Endocrinol Metab. 2009;20(7):318–24.PubMedCrossRef
85.
Delgado-González E, Sánchez-Tusie AA, Morales G, Aceves C, Anguiano B. Triiodothyronine attenuates prostate cancer progression mediated by β-adrenergic stimulation. Mol Med. 2016;22:1–11.PubMedPubMedCentralCrossRef
86.
87.
Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol. 2016;21(462):473.
88.
Shen W, Pei P, Zhang C, Li J, Han X, Liu T, et al. A polymeric hydrogel to eliminate programmed death-ligand 1 for enhanced tumor radio-immunotherapy. ACS Nano. 2023;17(23):23998–4011.PubMedCrossRef
89.
Mousa S, Davis F, Mohamed S, Davis P, Feng X. Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol. 2006;25(4):407.PubMed
90.
Mousa SA, O’Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ. The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol. 2005;46(3):356–60.PubMedCrossRef
91.
Bergh JJ, Lin H-Y, Lansing L, Mohamed SN, Davis FB, Mousa S, et al. Integrin αVβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology. 2005;146(7):2864–71.PubMedCrossRef
92.
Mostafavi A, Jafarnejad S, Khavandi S, Tabatabaee SA. Effect of vitamin D deficiency on coronary artery stenosis. Iran Heart J. 2015;16(3):38–44.
93.
Lin H-Y, Chin Y-T, Nana AW, Shih Y-J, Lai H-Y, Tang H-Y, et al. Actions of l-thyroxine and nano-diamino-tetrac (nanotetrac) on PD-L1 in cancer cells. Steroids. 2016;114:59–67.PubMedCrossRef
94.
Rodríguez-Molinero A, Hercbergs A, Sarrias M, Yuste A. Plasma 3, 3’, 5-Triiodo-L-thyronine [T3] level mirrors changes in tumor markers in two cases of metastatic cancer of the breast and pancreas treated with exogenous L-T3. Cancer Biomark. 2018;21(2):433–8.PubMedPubMedCentralCrossRef
Metadata
Title
Association between thyroid disorders and extra-thyroidal cancers, a review
Authors
Xin Jia
Jingru Li
Zongliang Jiang
Publication date
15-03-2024
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-024-03434-3
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits